BioXcel (BTAI) Insider Filing: 480 RSU Shares Vest in Sept 2025
Rhea-AI Filing Summary
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), reported Form 4 transactions showing restricted stock units converting to shares on September 14 and 15, 2025. Table II lists 163 underlying shares from RSUs reported 09/14/2025 and 317 underlying shares from RSUs reported 09/15/2025, each recorded at $0. The form explains that each RSU equals one share and notes prior grants of 521 RSUs on March 14, 2022 and 562 RSUs on March 15, 2023 with scheduled vesting (25% after one year, then 6.25% quarterly). The filing was signed by an attorney-in-fact on 09/16/2025.
Positive
- Timely disclosure of RSU vesting and resulting beneficial ownership changes for an officer
- Clear explanation that each RSU converts to one share and citation of original grant dates and vesting schedule
Negative
- None.
Insights
TL;DR Insider reported RSU vesting into 480 shares across two dates, a routine disclosure with limited market impact.
The Form 4 shows vesting-related transactions for the companys Chief Scientific Officer. The document records 163 and 317 underlying shares from RSUs on 09/14/2025 and 09/15/2025 respectively, at $0 per share, consistent with scheduled vesting from prior grants in 2022 and 2023. This is a standard insider compensation recognition rather than an open-market trade and likely does not change share supply materially. Disclosure timing and detail appear complete based on the form.
TL;DR The filing documents routine vesting of long-term incentive awards; it aligns with standard vesting schedules and governance disclosure practices.
The explanatory section confirms each RSU converts to one share and references the original grant dates and vesting cadence (25% at year one, then 6.25% quarterly). The use of an attorney-in-fact signature is noted and the Form 4 lists the Reporting Persons role as Chief Scientific Officer. There are no departures from expected grant terms disclosed in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 35 | $0.00 | -- |
| Exercise | Common Stock | 35 | $0.00 | -- |
| Exercise | Restricted Stock Units | 33 | $0.00 | -- |
| Exercise | Common Stock | 33 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
